Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Brooks V. Udelsman is active.

Publication


Featured researches published by Brooks V. Udelsman.


Proceedings of the National Academy of Sciences of the United States of America | 2010

Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling

Jason D. Roh; Rajendra Sawh-Martinez; Matthew P. Brennan; Steven M. Jay; Lesley Devine; Deepak A. Rao; Tai Yi; Tamar L. Mirensky; Ani Nalbandian; Brooks V. Udelsman; Narutoshi Hibino; Toshiharu Shinoka; W. Mark Saltzman; Edward L. Snyder; Themis R. Kyriakides; Jordan S. Pober; Christopher K. Breuer

Biodegradable scaffolds seeded with bone marrow mononuclear cells (BMCs) are the earliest tissue-engineered vascular grafts (TEVGs) to be used clinically. These TEVGs transform into living blood vessels in vivo, with an endothelial cell (EC) lining invested by smooth muscle cells (SMCs); however, the process by which this occurs is unclear. To test if the seeded BMCs differentiate into the mature vascular cells of the neovessel, we implanted an immunodeficient mouse recipient with human BMC (hBMC)-seeded scaffolds. As in humans, TEVGs implanted in a mouse host as venous interposition grafts gradually transformed into living blood vessels over a 6-month time course. Seeded hBMCs, however, were no longer detectable within a few days of implantation. Instead, scaffolds were initially repopulated by mouse monocytes and subsequently repopulated by mouse SMCs and ECs. Seeded BMCs secreted significant amounts of monocyte chemoattractant protein-1 and increased early monocyte recruitment. These findings suggest TEVGs transform into functional neovessels via an inflammatory process of vascular remodeling.


Heart | 2013

Tissue engineering of blood vessels in cardiovascular disease: moving towards clinical translation

Brooks V. Udelsman; Mark W. Maxfield; Christopher K. Breuer

Tissue engineering focuses on the construction of three-dimensional neotissues from their cellular components. Neotissue can be used to repair or replace tissues that are missing, damaged, or diseased. Despite its relative youth, the field has undergone significant growth. Vascular tissue engineering is at the forefront in the translation of this technology, as tissue engineered vascular grafts have already been successfully implanted in children with congenital heart disease. The purpose of this report is to review the advances in the understanding of tissue engineered vascular grafts as the technology moves to clinical translation.


PLOS ONE | 2016

Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model

Takuma Fukunishi; Cameron A. Best; Tadahisa Sugiura; Toshihiro Shoji; Tai Yi; Brooks V. Udelsman; Devan Ohst; Chin Siang Ong; Huaitao Zhang; Toshiharu Shinoka; Christopher K. Breuer; Jed Johnson; Narutoshi Hibino

Tissue engineered vascular grafts (TEVGs) have the potential to overcome the issues faced by existing small diameter prosthetic grafts by providing a biodegradable scaffold where the patient’s own cells can engraft and form functional neotissue. However, applying classical approaches to create arterial TEVGs using slow degrading materials with supraphysiological mechanical properties, typically results in limited host cell infiltration, poor remodeling, stenosis, and calcification. The purpose of this study is to evaluate the feasibility of novel small diameter arterial TEVGs created using fast degrading material. A 1.0mm and 5.0mm diameter TEVGs were fabricated with electrospun polycaprolactone (PCL) and chitosan (CS) blend nanofibers. The 1.0mm TEVGs were implanted in mice (n = 3) as an unseeded infrarenal abdominal aorta interposition conduit., The 5.0mm TEVGs were implanted in sheep (n = 6) as an unseeded carotid artery (CA) interposition conduit. Mice were followed with ultrasound and sacrificed at 6 months. All 1.0mm TEVGs remained patent without evidence of thrombosis or aneurysm formation. Based on small animal outcomes, sheep were followed with ultrasound and sacrificed at 6 months for histological and mechanical analysis. There was no aneurysm formation or calcification in the TEVGs. 4 out of 6 grafts (67%) were patent. After 6 months in vivo, 9.1 ± 5.4% remained of the original scaffold. Histological analysis of patent grafts demonstrated deposition of extracellular matrix constituents including elastin and collagen production, as well as endothelialization and organized contractile smooth muscle cells, similar to that of native CA. The mechanical properties of TEVGs were comparable to native CA. There was a significant positive correlation between TEVG wall thickness and CD68+ macrophage infiltration into the scaffold (R2 = 0.95, p = 0.001). The fast degradation of CS in our novel TEVG promoted excellent cellular infiltration and neotissue formation without calcification or aneurysm. Modulating host macrophage infiltration into the scaffold is a key to reducing excessive neotissue formation and stenosis.


PLOS ONE | 2015

Development of small diameter nanofiber tissue engineered arterial grafts.

Hirotsugu Kurobe; Mark W. Maxfield; Shuhei Tara; Kevin A. Rocco; Paul S. Bagi; Tai Yi; Brooks V. Udelsman; Zhen W. Zhuang; Yasuko Iwakiri; Christopher K. Breuer; Toshiharu Shinoka

The surgical repair of heart and vascular disease often requires implanting synthetic grafts. While synthetic grafts have been successfully used for medium-to-large sized arteries, applications for small diameter arteries (<6 mm) is limited due to high rates of occlusion by thrombosis. Our objective was to develop a tissue engineered vascular graft (TEVG) for small diameter arteries. TEVGs composed of polylactic acid nanofibers with inner luminal diameter between 0.5 and 0.6 mm were surgically implanted as infra-renal aortic interposition conduits in 25 female C17SCID/bg mice. Twelve mice were given sham operations. Survival of mice with TEVG grafts was 91.6% at 12 months post-implantation (sham group: 83.3%). No instances of graft stenosis or aneurysmal dilatation were observed over 12 months post-implantation, assessed by Doppler ultrasound and microCT. Histologic analysis of explanted TEVG grafts showed presence of CD31-positive endothelial monolayer and F4/80-positive macrophages after 4, 8, and 12 months in vivo. Cells positive for α-smooth muscle actin were observed within TEVG, demonstrating presence of smooth muscle cells (SMCs). Neo-extracellular matrix consisting mostly of collagen types I and III were observed at 12 months post-implantation. PCR analysis supports histological observations. TEVG group showed significant increases in expressions of SMC marker, collagen-I and III, matrix metalloproteinases-2 and 9, and itgam (a macrophage marker), when compared to sham group. Overall, patency rates were excellent at 12 months after implantation, as structural integrity of these TEVG. Tissue analysis also demonstrated vessel remodeling by autologous cell.


Journal of Biomechanics | 2014

Characterization of evolving biomechanical properties of tissue engineered vascular grafts in the arterial circulation.

Brooks V. Udelsman; Kristin S. Miller; Ethan W. Dean; Matthew R. Bersi; Kevin A. Rocco; Tai Yi; Jay D. Humphrey; Christopher K. Breuer

We used a murine model to assess the evolving biomechanical properties of tissue engineered vascular grafts (TEVGs) implanted in the arterial circulation. The initial polymeric tubular scaffold was fabricated from poly(lactic acid)(PLA) and coated with a 50:50 copolymer of poly(caprolactone) and poly(lactic acid)(P[PC/LA]). Following seeding with syngeneic bone marrow derived mononuclear cells, TEVGs (n=50) were implanted as aortic interposition grafts in wild-type mice and monitored serially using ultrasound. A custom biaxial mechanical testing device was used to quantify the in vitro circumferential and axial mechanical properties of grafts explanted at 3 or 7 months. At both times, TEVGs were much stiffer than native tissue in both directions. Repeated mechanical testing of some TEVGs treated with elastase or collagenase suggested that elastin did not contribute significantly to the overall stiffness whereas collagen did contribute. Traditional histology and immunostaining revealed smooth muscle cell layers, significant collagen deposition, and increasing elastin production in addition to considerable scaffold at both 3 and 7 months, which likely dominated the high stiffness seen in mechanical testing. These results suggest that PLA has inadequate in vivo degradation, which impairs cell-mediated development of vascular neotissue having properties closer to native arteries. Assessing contributions of individual components, such as elastin and collagen, to the developing neovessel is needed to guide computational modeling that may help to optimize the design of the TEVG.


Journal of Clinical Densitometry | 2013

Surgery in Primary Hyperparathyroidism: Extensive Personal Experience

Brooks V. Udelsman; Robert Udelsman

Parathyroidectomy is the optimal treatment for primary hyperparathyroidism (PHPT) and provides a cure in the vast majority of cases. Over the last 2 decades, improvements in preoperative localization and the development of intraoperative parathyroid hormone monitoring have opened the door for new surgical approaches to parathyroidectomy. Minimally invasive parathyroidectomy is performed under regional or local anesthesia. It requires less surgical dissection resulting in decreased trauma to tissues and is more effective and less costly than traditional bilateral cervical exploration. This article reviews our approach reflecting advances in preoperative localization, anesthetic techniques, and intraoperative management of patients undergoing parathyroidectomy for the treatment of PHPT.


Tissue Engineering Part C-methods | 2016

Biaxial Stretch Improves Elastic Fiber Maturation, Collagen Arrangement, and Mechanical Properties in Engineered Arteries.

Angela H. Huang; Jenna L. Balestrini; Brooks V. Udelsman; Kevin C. Zhou; Liping Zhao; Jacopo Ferruzzi; Barry Starcher; Michael J. Levene; Jay D. Humphrey; Laura E. Niklason

Tissue-engineered blood vessels (TEVs) are typically produced using the pulsatile, uniaxial circumferential stretch to mechanically condition and strengthen the arterial grafts. Despite improvements in the mechanical integrity of TEVs after uniaxial conditioning, these tissues fail to achieve critical properties of native arteries such as matrix content, collagen fiber orientation, and mechanical strength. As a result, uniaxially loaded TEVs can result in mechanical failure, thrombus, or stenosis on implantation. In planar tissue equivalents such as artificial skin, biaxial loading has been shown to improve matrix production and mechanical properties. To date however, multiaxial loading has not been examined as a means to improve mechanical and biochemical properties of TEVs during culture. Therefore, we developed a novel bioreactor that utilizes both circumferential and axial stretch that more closely simulates loading conditions in native arteries, and we examined the suture strength, matrix production, fiber orientation, and cell proliferation. After 3 months of biaxial loading, TEVs developed a formation of mature elastic fibers that consisted of elastin cores and microfibril sheaths. Furthermore, the distinctive features of collagen undulation and crimp in the biaxial TEVs were absent in both uniaxial and static TEVs. Relative to the uniaxially loaded TEVs, tissues that underwent biaxial loading remodeled and realigned collagen fibers toward a more physiologic, native-like organization. The biaxial TEVs also showed increased mechanical strength (suture retention load of 303 ± 14.53 g, with a wall thickness of 0.76 ± 0.028 mm) and increased compliance. The increase in compliance was due to combinatorial effects of mature elastic fibers, undulated collagen fibers, and collagen matrix orientation. In conclusion, biaxial stretching is a potential means to regenerate TEVs with improved matrix production, collagen organization, and mechanical properties.


ASME 2013 Conference on Frontiers in Medical Devices: Applications of Computer Modeling and Simulation | 2013

Computational Growth and Remodeling Model for Evolving Tissue Engineered Vascular Grafts in the Venous Circulation

Kristin S. Miller; Brooks V. Udelsman; Yong-Ung Lee; Yuji Naito; Christopher K. Breuer; Jay D. Humphrey

The field of vascular tissue engineering continues to advance rapidly, yet there is a pressing need to understand better the time course of polymer degradation and the sequence of cell-mediated matrix deposition and organization. Mounting evidence suggests that cells respond to mechanical perturbations through a process of growth and remodeling (G&R) to establish, maintain, and restore a preferred state of homeostatic stress. Previous computational models utilizing G&R approaches have captured arterial responses to diverse changes in mechanical loading [1, 8, 9]. Recently, a G&R framework was also introduced to account for the kinetics of polymer degradation as well as synthesis and degradation of neotissue constituents [5]. Niklason et al. demonstrated that models of G&R can predict both evolving tissue composition and mechanical behavior after extended periods of in vitro culture of polymer-based tissue-engineered vascular grafts (TEVGs), thus providing insights into the timecourse of neotissue formation and polymer removal. Moreover, they suggest that models of G&R can be powerful tools for the future refinement and optimization of scaffold designs. Nevertheless, such computational models have not yet been developed for examining the formation of neotissue following the implantation of a polymeric TEVG in vivo.Copyright


Regenerative Medicine Applications in Organ Transplantation | 2014

Vessel Regeneration and Bioengineering

Shuhei Tara; Ethan W. Dean; Kevin A. Rocco; Brooks V. Udelsman; Hirotsugu Kurobe; Toshiharu Shinoka; Christopher K. Breuer

Over the last decade, advancements in the field of vascular tissue engineering have generated a variety of novel treatment strategies for patients with cardiac defects and vascular disease. Notably, the technique of seeding cells onto biodegradable polymeric scaffolds to create tissue-engineered vascular grafts (TEVGs) allows for the formation of organized neovascular tissue and enables the implanted construct to grow with the patient. Studies in animal models have resulted in a greater understanding of the complex and dynamic processes behind neovessel development and enabled the creation of a TEVG seeded with bone marrow-derived mononuclear cells for use in a pilot clinical trial. Current research indicates that this tissue engineering approach is safe and effective, and the ongoing translation of this technology holds great promise. In this text, we review the scaffold materials, cell types, and seeding methods for TEVG creation, and we introduce our clinical application of TEVGs.


Journal of Palliative Medicine | 2018

Natural Language Processing to Assess End-of-Life Quality Indicators in Cancer Patients Receiving Palliative Surgery

Charlotta Lindvall; Elizabeth J. Lilley; Sophia N. Zupanc; Isabel Chien; Brooks V. Udelsman; Anne M. Walling; Zara Cooper; James A. Tulsky

BACKGROUND Palliative surgical procedures are frequently performed to reduce symptoms in patients with advanced cancer, but quality is difficult to measure. OBJECTIVE To determine whether natural language processing (NLP) of the electronic health record (EHR) can be used to (1) identify a population of cancer patients receiving palliative gastrostomy and (2) assess documentation of end-of-life process measures in the EHR. DESIGN/SETTING Retrospective cohort study of 302 adult cancer patients who received a gastrostomy tube at a single tertiary medical center. MEASUREMENTS Sensitivity and specificity of NLP compared to gold standard of manual chart abstraction in identifying a palliative indication for gastrostomy tube placement and documentation of goals of care discussions, code status determination, palliative care referral, and hospice assessment. RESULTS Among 302 cancer patients who underwent gastrostomy, 68 (22.5%) were classified by NLP as having a palliative indication for the procedure compared to 71 patients (23.5%) classified by human coders. Human chart abstraction took >2600 times longer than NLP (28 hours vs. 38 seconds). NLP identified the correct patients with 95.8% sensitivity and 97.4% specificity. NLP also identified end-of-life process measures with high sensitivity (85.7%-92.9%,) and specificity (96.7%-98.9%). In the two months leading up to palliative gastrostomy placement, 20.5% of patients had goals of care discussions documented. During the index hospitalization, 67.7% had goals of care discussions documented. CONCLUSIONS NLP offers opportunities to identify patients receiving palliative surgical procedures and can rapidly assess established end-of-life process measures with an accuracy approaching that of human coders.

Collaboration


Dive into the Brooks V. Udelsman's collaboration.

Top Co-Authors

Avatar

Christopher K. Breuer

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Toshiharu Shinoka

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tai Yi

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge